DRG Market Assessment reports

MARKET OVERVIEW Chronic hand eczema (CHE) is a painful and debilitating form of eczema localized to the hands that can seriously impact a patient’s quality of life. No prescription therapies…

The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments…

Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As…

The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications,…

Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved…

Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty in swallowing food and the…

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…

For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches…

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol Myers Squibb…

Scleroderma / systemic sclerosis (SSc) is characterized by progressive vasculopathy, progressive fibrosis, and autoimmunity. While disease severity and symptoms are heterogeneous, in general,…

Executive Insights report examining the commercial prospects for novel therapies for progressive supranuclear palsy (PSP) in the U.S., European, and Chinese markets. The report examines the current…

TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in…